logo
Plus   Neg
Share
Email

HCA Healthcare Enters Into JV With A Plus International To Make Surgical And Procedure Masks

HCA Healthcare Inc. (HCA) said Thursday it has entered into a new joint venture business with A Plus International Inc., a manufacturer of healthcare products, to expand access to personal protective equipment or PPE by manufacturing surgical and procedure masks in the United States.

The new business entity is part of HCA Healthcare's continued effort to support healthcare workers and address the global demand for PPE.

Under the joint venture, HCA Healthcare expects production of Level 1 and Level 3 masks that meet American Society for Testing and Materials or ASTM standards for quality and safety to begin in early 2021 from a manufacturing center in Asheville, North Carolina.

The investment in the new business entity will initially be funded equally by HCA Healthcare Mission Fund, LLC, an affiliate of HCA Healthcare, and A Plus.

HCA Healthcare noted that its 2020 spending for PPE increased by more than $196 million from 2019.

Supporting the supply chain of hospitals and non-acute providers, HealthTrust, a leader in purchasing aggregation and performance improvement for healthcare, will co-manage the joint venture with A Plus.

HealthTrust's wholly owned subsidiary, Resource Optimization & Innovation or ROi, will serve as the distribution partner for the business. Roi will provide access to PPE inventories to HealthTrust member organizations in the U.S.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
United Airlines is adding three new flights to Croatia, Greece and Iceland, which are starting to reopen to vaccinated visitors. The move would give travelers more options for summer travel by flying direct to these countries. Last month's searches on United.com for flights to Croatia, Greece and Iceland were up 61 percent. Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies.
Follow RTT